Archives
Apicidin: Selective Histone Deacetylase Inhibitor Evidence R
Apicidin: Selective Histone Deacetylase Inhibitor Evidence Review
Executive Summary: Apicidin is a natural fungal metabolite and selective histone deacetylase inhibitor (HDACi) that potently inhibits HDAC3 (IC50: 15.8 nM) and HDAC6 (IC50: 665.1 nM), leading to increased histone acetylation and altered gene expression (source: product_spec). It exhibits robust anti-proliferative effects in cancer cell lines and suppresses tumor growth in vivo at 5 mg/kg via intraperitoneal administration (source: product_spec). Apicidin impairs oocyte maturation by disrupting spindle assembly and increasing chromatin acetylation, highlighting its relevance for both oncology and reproductive toxicology (source: paper). It is increasingly detected as an emerging mycotoxin in food and animal feed, raising safety concerns (source: paper). For laboratory use, it is DMSO/ethanol soluble and requires careful handling for experimental reproducibility (source: product_spec).
Biological Rationale
Apicidin is a cyclic tetrapeptide isolated from Fusarium pallidoroseum and is classified as both a secondary fungal metabolite and an emerging mycotoxin (source: paper). Its principal biological activity is the inhibition of histone deacetylases, enzymes that remove acetyl groups from lysine residues on histone proteins, thereby regulating chromatin compaction and transcriptional activity. HDACs play critical roles in cell cycle progression, apoptosis, and differentiation. Dysregulated HDAC activity is implicated in cancer, inflammation, and developmental disorders. By targeting HDAC3 and HDAC6, Apicidin modulates gene expression and cellular phenotype, making it a valuable tool in both oncology and epigenetics research (source: product_spec). Its detection in food and feed highlights a dual role as a potential toxicant and a molecular tool.
Mechanism of Action of Apicidin
Apicidin acts as a selective inhibitor of class I (notably HDAC3) and class IIb (HDAC6) histone deacetylases. The compound binds to the HDAC active site, competitively blocking substrate access. This inhibition increases acetylation of histone H3 (notably H3K14) and H4 (H4K16) residues, as well as non-histone substrates like α-tubulin (source: paper). Enhanced acetylation disrupts chromatin structure, loosening DNA-histone interactions and promoting transcription of cell cycle regulators and pro-apoptotic genes. In reproductive biology, Apicidin downregulates HDAC1 and HDAC3 mRNA in oocytes, impairs spindle assembly, and induces chromosomal misalignment, resulting in meiotic arrest and apoptosis (source: paper). In cancer models, this mechanism translates to anti-proliferative and anti-angiogenesis effects (source: product_spec).
Evidence & Benchmarks
- Apicidin inhibits HDAC3 with an IC50 of 15.8 nM and HDAC6 with an IC50 of 665.1 nM in biochemical assays (source: product_spec).
- Exposure to Apicidin (AP) in oocytes increases acetylation of H3K14, H4K16, and α-tubulin, disrupts spindle assembly, and delays meiotic progression (source: paper).
- In vivo, intraperitoneal administration of Apicidin at 5 mg/kg/day for 21 days suppresses tumor growth in HCT-116 colon carcinoma and Ishikawa endometrial cancer xenografts (source: product_spec).
- When included in animal feed at 0.05%, Apicidin is lethal to rats within 10–14 days, indicating potent systemic toxicity at high doses (source: paper).
- Apicidin is detected in 65–85% of global swine and poultry feed samples at mean concentrations of 19–22 μg/kg (source: paper).
- Apicidin stock solutions are optimally prepared in DMSO or ethanol, with warming to 37°C and ultrasonic shaking recommended for cell culture use (source: product_spec).
This article extends the discussion in Apicidin: Translating Epigenetic Disruption into Research Impact by providing a granular summary of numeric toxicity, detection, and in vivo efficacy benchmarks. For detailed applied workflows, see also Apicidin as a Histone Deacetylase Inhibitor: Applied Workflows, which focuses on bench protocols; this review clarifies quantitative endpoints and mechanistic boundaries. For a full guide to protocol enhancements and product sourcing, Apicidin: Histone Deacetylase Inhibitor for Targeted Research provides actionable steps, while this article synthesizes new toxicological and mechanistic evidence.
Applications, Limits & Misconceptions
Apicidin's selective HDAC inhibition underpins its use as a cancer cell growth inhibitor, anti-angiogenesis compound, and tool for studying epigenetic regulation. It is valuable in dissecting chromatin dynamics, cell cycle checkpoints, and apoptotic pathways. However, recent evidence underscores its role as a mycotoxin with reproductive toxicity risks and systemic effects at high exposures (source: paper). Researchers must distinguish its controlled research application from inadvertent dietary exposure.
Common Pitfalls or Misconceptions
- Apicidin is not suitable for diagnostic or therapeutic use in humans; its use is strictly for research (source: product_spec).
- High-dose or chronic exposure in vivo, especially via feed, can be lethal to animals and is not representative of laboratory model exposures (source: paper).
- The selectivity for HDAC3 and HDAC6 does not imply exclusivity; off-target effects and broader epigenetic disruption are possible at higher concentrations (source: paper).
- Improper storage (e.g., room temperature, repeated freeze-thaw) leads to rapid compound degradation and loss of activity (source: product_spec).
- Detection of Apicidin as a contaminant in crops or feed is not an indicator of its suitability for scientific experimentation; only certified preparations (e.g., from APExBIO) are appropriate for research use.
Workflow Integration & Parameters
Protocol Parameters
- assay: HDAC3 inhibition | value_with_unit: IC50 15.8 nM | applicability: enzyme assays, chromatin studies | rationale: benchmark potency for target engagement | source_type: product_spec
- assay: HDAC6 inhibition | value_with_unit: IC50 665.1 nM | applicability: tubulin acetylation, cytoskeleton studies | rationale: secondary selectivity profile | source_type: product_spec
- assay: Tumor growth suppression | value_with_unit: 5 mg/kg/day i.p. x 21 days | applicability: xenograft mouse models | rationale: in vivo efficacy benchmark | source_type: product_spec
- assay: Oocyte meiotic maturation | value_with_unit: 1–10 μM | applicability: in vitro oocyte culture | rationale: recapitulates spindle and chromatin disruption | source_type: DOI
- assay: Stock solution preparation | value_with_unit: dissolve in DMSO or ethanol, warm to 37°C | applicability: cell culture, biochemical assays | rationale: ensures solubility, prevents precipitation | source_type: workflow_recommendation
- assay: Storage | value_with_unit: -20°C, minimize freeze-thaw cycles | applicability: compound stability | rationale: prevents degradation | source_type: workflow_recommendation
Conclusion & Outlook
Apicidin, as supplied by APExBIO, is a powerful selective HDAC inhibitor that bridges oncology and reproductive toxicology research. Its activity profile enables detailed study of chromatin regulation, cancer cell growth inhibition, and the mechanistic underpinnings of epigenetic toxicants. Widespread detection in food and feed highlights the importance of vigilance regarding its dual role as a research tool and potential contaminant. Further translational research will clarify safe handling, mechanistic boundaries, and optimal deployment in targeted studies (source: paper; product_spec).